Market launch with the company’s actively managed retail fund line, digital portfolio management and individual asset management from the 2nd quarter of 2019
New preclinical data in Cancer Immunology Research demonstrate that increasing tumor-infiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition
NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors
NOXXON Supervisory Board elects experienced US & EU Biotech Veteran Don deBethizy Chairman
NOXXON provides Update on ongoing Phase 1/2 clinical Trial with Lead Program NOX-A12
NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with KEYTRUDA® in metastatic pancreatic and colorectal cancer
NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/KEYTRUDA® Phase 1/2 combination trial
NOXXON PHARMA secures a private placement of €1 million and additional financing of up to €10 million through convertible notes with share subscritpion warrants attached to finance further clinical development of NOX-A12
NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO
NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion